Biodexa Pharmaceuticals PLC
BDRX0.920USD
+0.054+6.22%
Cierre 06/23, 16:00（ET）Cotizaciones retrasadas 15 min
6.15BCap. mercado
--P/E TTM
Más Datos de Biodexa Pharmaceuticals PLC Compañía
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
Información de la empresa
Símbolo de cotizaciónBDRX
Nombre de la empresaBiodexa Pharmaceuticals PLC
Fecha de salida a bolsaDec 08, 2014
Fundada en2014
Director ejecutivoMr. Stephen A. Stamp
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalDec 08
Dirección1 Caspian Point
CiudadABINGDON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited Kingdom
Código postalCF10 4DQ
Teléfono4401235888300
Sitio Webhttps://www.biodexapharma.com/
Símbolo de cotizaciónBDRX
Fecha de salida a bolsaDec 08, 2014
Fundada en2014
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
--
--
Dr. Sijmen (Sijmen) De Vries, M.D.
Dr. Sijmen (Sijmen) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Controller
Group Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
--
--
Dr. Sijmen (Sijmen) De Vries, M.D.
Dr. Sijmen (Sijmen) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Controller
Group Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
Divisa: GBPActualizado: dom., 6 de abr
Divisa: GBPActualizado: dom., 6 de abr
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Sin datos
Por regiónGBP
Nombre
Ganancia
Proporción
Belgium
381.00K
100.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: lun., 2 de jun
Actualizado: lun., 2 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Cavalry Fund I Management, LLC
3.47%
Brio Capital Management LLC
3.32%
Abbe (Richard)
0.48%
Bukwang Pharmaceutical Co., Ltd.
0.28%
Melior Pharmaceuticals I, Inc.
0.28%
Other
92.17%
Accionistas
Accionistas
Proporción
Cavalry Fund I Management, LLC
3.47%
Brio Capital Management LLC
3.32%
Abbe (Richard)
0.48%
Bukwang Pharmaceutical Co., Ltd.
0.28%
Melior Pharmaceuticals I, Inc.
0.28%
Other
92.17%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
6.82%
Corporation
0.69%
Individual Investor
0.48%
Investment Advisor
0.46%
Bank and Trust
0.20%
Venture Capital
0.11%
Hedge Fund
0.10%
Research Firm
0.01%
Other
91.13%
Participación institucional
Actualizado: sáb., 22 de feb
Actualizado: sáb., 22 de feb
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
37
260.22K
10.16%
+146.72K
2024Q4
37
258.63K
38.68%
+145.03K
2024Q3
39
166.61K
38.54%
+138.41K
2024Q2
36
78.92K
24.69%
+69.19K
2024Q1
28
31.04K
21.44%
+27.53K
2023Q4
30
32.82K
23.15%
+31.84K
2023Q3
21
574.00
6.29%
-2.15K
2023Q2
21
425.00
5.59%
-1.99K
2023Q1
22
183.00
8.18%
-2.20K
2022Q4
21
54.00
9.96%
+24.00
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Brio Capital Management LLC
167.68K
25.08%
+110.57K
+193.59%
Nov 14, 2024
Abbe (Richard)
24.34K
3.64%
+24.34K
--
Jul 19, 2024
Bukwang Pharmaceutical Co., Ltd.
14.18K
2.12%
+14.18K
--
Apr 01, 2024
Melior Pharmaceuticals I, Inc.
14.18K
2.12%
+14.18K
--
Apr 01, 2024
Mercer Street Capital Partners, LLC
14.18K
2.12%
+7.93K
+126.83%
Apr 01, 2024
UBS Financial Services, Inc.
7.05K
1.05%
-3.17K
-31.03%
Dec 31, 2024
GS Capital Partners LLC
6.31K
0.94%
+6.31K
--
Apr 01, 2024
Ionic Ventures LLC
5.42K
0.81%
+5.33K
+5.92K%
Dec 31, 2023
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Fecha
Tipo
Relación
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Mar 16, 2023
Merger
4<1
Mar 16, 2023
Merger
4<1
Ver más
